XBI icon

SPDR S&P Biotech ETF

91.28 USD
+1.47
1.64%
At close Dec 20, 4:00 PM EST
After hours
91.68
+0.40
0.44%
1 day
1.64%
5 days
-2.27%
1 month
-2.90%
3 months
-10.17%
6 months
1.55%
Year to date
1.16%
1 year
10.43%
5 years
-5.60%
10 years
44.96%
0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

17% more funds holding in top 10

Funds holding in top 10: 18 [Q2] → 21 (+3) [Q3]

11% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 82

1% more funds holding

Funds holding: 749 [Q2] → 758 (+9) [Q3]

4% more capital invested

Capital invested by funds: $9.75B [Q2] → $10.1B (+$402M) [Q3]

8.52% less ownership

Funds ownership: 138.32% [Q2] → 129.8% (-8.52%) [Q3]

13% less repeat investments, than reductions

Existing positions increased: 234 | Existing positions reduced: 269

16% less call options, than puts

Call options by funds: $2.8B | Put options by funds: $3.33B

Research analyst outlook

We haven’t received any recent analyst ratings for XBI.

Financial journalist opinion

Based on 3 articles about XBI published over the past 30 days

Positive
Market Watch
1 week ago
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thursday.
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Neutral
Zacks Investment Research
2 weeks ago
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Neutral
Seeking Alpha
3 weeks ago
Finding Winners In Biotech, Probably The Riskiest Sector
Investing in biotech offers high upside but comes with significant risks, especially with volatile stock movements and binary outcomes from clinical trials, says Jonathan Faison. Focus on multi-year clinical and commercial momentum, diversifying with multiple drug candidates.
Finding Winners In Biotech, Probably The Riskiest Sector
Positive
MarketBeat
1 month ago
Is Biotech's Bull Run Over? Examining Election Impacts
The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump's election win on November 5, biotech ETFs like the iShares Biotechnology ETF NASDAQ: IBB and the SPDR Biotech ETF NYSE: XBI stopped short of new 52-week highs.
Is Biotech's Bull Run Over? Examining Election Impacts
Positive
Seeking Alpha
1 month ago
Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)
Biotech had its worst weekly performance since 2020 last week, driven by the post-election rally fizzling and fears surrounding RFK Jr.'s potential impact on the FDA. Concerns about Mr. Kennedy leading the HHS are likely overblown; his confirmation is uncertain, and his focus may impact the food sector more than biotech. The biotech sector appears oversold with little “froth,” especially compared to the overall market, suggesting a buying opportunity for long-term investors.
Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)
Positive
Zacks Investment Research
1 month ago
5 Top-Ranked ETFs to Buy on the Dip
Investors can take advantage of beaten-down prices because the second Trump administration is likely to boost stocks.
5 Top-Ranked ETFs to Buy on the Dip
Negative
Zacks Investment Research
1 month ago
Trump Taps RFK for HHS: Time to Avoid Biotech?
With Trump's appointment of Robert F. Kennedy Jr. as the secretary of Health and Human Services, the biotech industry has more questions than answers.
Trump Taps RFK for HHS: Time to Avoid Biotech?
Neutral
CNBC Television
1 month ago
Trade Tracker: Joe Terranova sells Amgen and buys XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss his latest portfolio moves.
Trade Tracker: Joe Terranova sells Amgen and buys XBI
Positive
Investors Business Daily
1 month ago
Biotech Stocks Edge Higher. Could Trump 2.0 Mean More Innovation, Dealmaking?
Biotech stocks jumped early Wednesday on hopes for more innovation and dealmaking after Donald Trump clinched his second presidency. The post Biotech Stocks Edge Higher.
Biotech Stocks Edge Higher. Could Trump 2.0 Mean More Innovation, Dealmaking?
Neutral
Zacks Investment Research
1 month ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
A smart beta exchange traded fund, the SPDR S&P Biotech ETF (XBI) debuted on 01/31/2006, and offers broad exposure to the Health Care ETFs category of the market.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Charts implemented using Lightweight Charts™